Telaprevir in Combination With Standard of Care in Hepatitis C Genotype 1 Infection in Patients With Hepatocellular Carcinoma Awaiting Liver Transplantation

Trial Profile

Telaprevir in Combination With Standard of Care in Hepatitis C Genotype 1 Infection in Patients With Hepatocellular Carcinoma Awaiting Liver Transplantation

Discontinued
Phase of Trial: Phase III

Latest Information Update: 14 Mar 2015

At a glance

  • Drugs Telaprevir (Primary) ; Peginterferon alfa-2a; Ribavirin
  • Indications Hepatitis C
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 20 Feb 2014 Status changed from recruiting to discontinued as reported by M.D. Anderson Cancer Center record.
    • 20 Apr 2013 Status changed from not yet recruiting to recruiting as reported by M.D. Anderson Cancer Center record.
    • 20 Apr 2013 New source identified and integrated (M.D. Anderson Cancer Center; 2012-0977).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top